Czech/SlovakiaCzech RepublicSlovakia

US Agri-Giant Awaits First TimeClearance for GM Seeds in Europe

16.09.2003

Prague - The Czech Ministry of Environment has postponed a decision on the application by US agriculture giant Monsanto Corp. for clearance for so-called 'Bt Maize' for commercial production until an expert commission gives its opinion. Monsanto, the world's largest supplier of GM seeds, is the first company to ask Czech authorities to approve commercial production of GM seeds - no European country has done this so far. The Bt Maize strain has the advantage of being toxic to the European corn borer, a common pest of the maize crop.
Currently Monsanto only grows this strain of maize experimentally in the Czech Republic at Branisovice, in South Moravia. The Czech Minister for the Environment Libor Ambrozek was originally expected to rule on the Monsanto application by the end of June but handed over the documents to the expert panel in July (see also page 36). According to government sources it is uncertain how long the commission could take to report back and when a final decision could be expected.
In the Czech Republic all food products containing GMOs must, according to new case-law since January 1, 2002, be cleared by the Ministry of Health. The products themselves must be labelled as “genetically modified” or containing “genetically-modified organisms”. More food made from genetically modified crops could be on the way following the July 2 decision of the European Parliament to drop its five-year ban on the introduction of new biotech products on the European Union (EU) market and allow GM foods into the EU as long as they are clearly labelled.
The Bt-toxin, a protein which is naturally expressed in the soil bacterium Bacillus thuringiensis, has the ability to destroy the intestinal wall of different varmints without harmfull side-effects for beneficial organisms. In humans most isoforms of Bt-toxin are non-toxic and digested very early in the gastro-intestinal tract. Only one Bt-toxin variant, called Cry9c, is suspected to cause allergic reactions. Back in September 2000 Cry9c-containing StarLinkTM corn by former Aventis CropScience caused a food scandal when it was found in the human food supply despite having been approved for animal feed use only.
Monsanto began field trials in the Czech Republic in August 2001 using herbizide resitant Roundup Ready wheat. While according to Czech media reports public support for the new technology was more widespread in the Czech Republic at that time than in other European countries, the Monsanto trial had aggravated the discussion. Especially Greenpeace objected to the trials. The environmentalists argued that Monsanto's wheat was likely to contaminate regular grown crops threatening the country's wheat export.

Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/us-agri-giant-awaits-first-timeclearance-for-gm-seeds-in-europe.html

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF117.6%
  • CELLECTIS (F)13.63 EUR101.0%
  • ADDEX (CH)4.29 CHF96.8%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3209.1%
  • GW PHARMACEUTICALS (UK)444.50 GBP845.7%
  • PAION (D)2.83 EUR328.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.92 EUR-72.2%

No liability assumed, Date: 10.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events